Norwegian researchers have previously demonstrated an association between diabetes and virus infection. New research shows that, among children with type 1 diabetes, treatment with antiviral drugs could help preserve insulin levels. The result shows that it is possible to slow down and eventually prevent type 1 diabetes.
-crop-1000x562.jpg)
In type 1 diabetes, the pancreas gradually stops producing insulin, a hormone which regulates the body's blood-sugar levels. The body needs insulin to convert sugar into energy.
When insulin production stops, you become completely dependent on supplying insulin to your body yourself. This means that a process that your body does automatically becomes something you actively have to monitor and manage, for the rest of your life.
A research breakthrough shows that antivirus drugs preserve insulin in children
In an international research breakthrough, Norwegian scientists have now shown that they are able to reduce some of the loss of insulin production in the body. They did this by administering antivirus medication to children and young people with newly diagnosed type 1 diabetes.
The study was conducted by a research group at the pediatric clinic at Oslo University Hospital (OUS) and the University of Oslo (UiO).
"The finding largely shows that a virus trigger type 1 diabetes in children," says Knut Dahl-Jørgensen, a senior physician at OUS and Senior Professor at UiO, who led the study.
"This means that it will be possible to treat and slow down type 1 diabetes with medication. Perhaps eventually even prevent the disease," he adds.
A completely new concept for treating type 1 diabetes
- This is a potensial new concept for the treatment of type 1 diabetes. No other research groups have done this before us, Lars Krogvold says.
The study is published in the renowned journal Nature Medicine. First authors are senior physician Lars Krogvold and PhD student Ida Mynarek.
Enterovirus causes chronic infection in the pancreas
The researchers have previously demonstrated a clinically significant association between enterovirus infection and onset of type 1 diabetes.
They detected a chronic viral infection in the pancreas tissue where insulin is produced, in patients with newly diagnosed type 1 diabetes.
"We have previously demonstrated a group of viruses called enterovirus, in patients recently diagnosed with type 1 diabetes. We found an enterovirus infection in the pancreas of all the patients we examined," Dahl-Jørgensen explains.
Enterovirus are very common viruses that can cause both respiratory infections and gastrointestinal illnesses.
The cells that produce insulin die
However, enterovirus does not usually belong in the pancreas. How does these viruses end up there, and how can they cause diabetes?
The researchers believe that some individuals are more vulnerable to establish a low-grade. chronic enterovirus infections than others. Over the past ten years, they have studied tissue samples from the pancreas in international laboratories.
"We have described a cascade of different mechanisms that we believe are destroying the cells, triggered by the viral infection," Dahl-Jørgensen explains, adding:
"Enterovirus creates a low-grade or slow-growing chronic infection in the insulin producing tissues in the pancreas. The immune system reacts to the virus by attacking the cells. This destroys the cells' capacity to produce the vital hormone insulin."
Patients received either antiviral medication or a placebo
The researchers wanted to investigate the association between enterovirus and type 1 diabetes more closely. They wanted to determine the effect of antiviral treatment on insulin production in children and adolescents newly diagnosed with type 1 diabetes.
They conducted a randomized, controlled trial in which 96 children aged 6-16 with newly diagnosed type 1 diabetes, were randomly assigned to one of two groups.
One group received treatment with two antiviral medications, pleconaril and ribavirin, for six months. The other group received a placebo, a treatment with no active ingredients. The patients started treatment immediately after being diagnosed.
The researchers then compared the two groups.
Higher levels of insulin in patients who received medication
After one year, the researchers measured the patients' insulin production.
"The level of insulin production in the body was found to be significantly higher in the group that received antiviral medication compared to the group that received the placebo," says Dahl-Jørgensen.
This means that the antiviral treatment slows down the progression of type 1 diabetes.
Why is it important for patients to preserve their insulin production?
Type 1 diabetes is a serious and demanding disease. No cure exists for type 1 diabetes, and there is nothing we can to do prevent it, yet.
The disease can lead to long-term complications, such as blindness, amputations, kidney failure, heart attacks, and reduced lifespan.
"If we can stop the virus before it destroys all the insulin-producing cells, patients will have a much milder disease to manage. They will have more stable and lower blood-sugar levels and may also have fewer serious complications in the long run," the Professor says.
Researchers hope to prevent type 1 diabetes
The researchers now want to test if antiviral medication will work better alone or when combined with medications that inhibit inflammation and strengthen the insulin-producing cells.
"Further studies are needed to confirm these results and optimize this anti-viral treatment. We strongly believe that a combination therapy with different medications will have an even greater effect," says Lars Krogvold.
"The ultimate goal is to contribute to stopping type 1 diabetes," he adds.
Can a vaccine prevent type 1 diabetes in the future?
In addition, the researchers will continue their research and test whether antiviral medication can also work at an earlier stage in the disease process. Perhaps it can prevent people with prediabetes from developing the disease?
"Prediabetes has no symptoms but can be detected by measuring specific antibodies in the blood," explains Krogvold.
In the long term, the researchers hope it will be possible to develop a vaccine against type 1 diabetes.
Their research collaborators in Finland have developed a protein-based vaccine against enterovirus. This vaccine will now be tested to see if it can prevent type 1 diabetes.
Research collaboration between several countries
The study is a Nordic collaboration and was conducted in Oslo and Copenhagen. Professor Jesper Johannessen at the University of Copenhagen led the study in Denmark.
Researchers from Tampere University in Finland, Linköping University in Sweden, and Cambridge University in the UK also contributed. The researchers collaborated with over twenty international research laboratories on the study, and are partners in the INNODIA consortium
Reference
Krogvold,L., Mynarek, I. M., Ponzi, E. et al. (2023). Residual insulin after anti-viral treatment with pleconaril and ribavirin in new onset type 1 diabetes. A phase 2, randomized, clinical trial. Nature Medicine. https://www.nature.com/articles/s41591-023-02576-1
